3 completed, 2 terminated, 1 suspended. 3 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Suspended 1, Terminated 1 |
| Phase 3 | 2 | Suspended 1, Terminated 1 |
Follow NUC-1031: new trials by email Literature Review of NUC-1031 trials Research Report on NUC-1031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer NUC-1031, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 3 | Terminated | NuCana plc | 773 | 2019-12-24 | 2023-05-24 |
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer NUC-1031 500 mg, NUC-1031 750mg - Ovarian Cancer | Phase 2 | Terminated | NuCana plc | 53 | 2017-09-28 | 2021-02-21 |
| ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers Acelarin, Cisplatin - Biliary Tract Cancer, Gallbladder Cancer | Phase 1 | Completed | The Christie NHS Foundation Trust | 21 | 2016-01-01 | 2023-05-17 |
| Acelarin First Line Randomised Pancreatic Study Acelarin, Gemcitabine - Pancreatic Acinar Carcinoma, Pancreatic Neoplasms | Phase 2 / Phase 3 | Suspended | The Clatterbridge Cancer Centre NHS Foundation Trust | 328 | 2015-12-01 | 2019-10-29 |
| Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Nuc-1031 and Carboplatin - Recurrent Ovarian Cancer | Phase 1 | Completed | Imperial College Healthcare NHS Trust | 25 | 2014-11-01 | 2021-05-18 |
| NUC-1031 in Patients With Advanced Solid Tumours NUC-1031 - Cancer | Phase 1 | Completed | Imperial College London | 68 | 2012-10-01 | 2024-03-20 |
Neoplasms (3) · Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Digestive System Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gallbladder Neoplasms (1) · Ovarian Diseases (1) · Pancreatic Neoplasms (1)
NuCana plc (2) · Imperial College Healthcare NHS Trust (1) · Imperial College London (1) · The Christie NHS Foundation Trust (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1)
United Kingdom (6) · United States (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1)
Daniel H Palmer, BSC, PhD (1) · Elisabeth Oelmann, MD PhD (1) · Jennifer Knox, MD (1) · Sarah Blagden, MBBS, MRCP (1)
PMID 32374623, PMID 33210382, PMID 39978598
2014 (1), 2015 (1), 2016 (1), 2019 (1)